恩替卡韦治疗慢乙肝患者血清及PBMC中HBVDNA变化的相关性研究

The association between HBVDNA in serum and PBMCs in chronic hepatitis B patients treated with Entecavir

目的研究恩替卡韦治疗慢性乙型肝炎(慢乙肝)患者期间血清及PBMC内HBVDNA变化的相关性。方法 73例慢乙肝患者,随机分为治疗组(38例)和对照组(35例),治疗组应用恩替卡韦0.5㎎/天】48周,分别于治疗后的0、4、12、24、48周检测血清及PBMC中HBVDNA。结果治疗后的4、12、24、48周治疗组患者血清HBVDNA阴转率分别为31.57%、81.58%、94.74%、97.37%,PBMC内HBVDNA阴转率分别为10.52%、42.11%、57.89%、76.32%,治疗后的12、24、48周血清和PBMC内HBVDNA阴转率治疗组与对照组相比较P【0.005,两组比较差异有显著性意义。结论恩替卡韦对慢乙肝患者血清及PBMC中HBVDNA均有明显的抑制作用,但PBMC中HBVDNA的阴转率低于血清HBVDNA的阴转率。

Objective The aim of this study was to assess the association between HBVDNA in serum and PBMCs in chronic hepatitis B patients treated with Ente- cavir.Methods 73 cases of chronic hepatitis B patients were randomly divided into treatment group( 38 cases) and control group( 35 cases) ,treatment group received entecavir 0.5 mg/day treatment > 48 weeks.HBVDNA in serum and PBMCs were assessed at baseline,during treatment( weeks 4,12,24and 48) .Results Serum HBVD-NA negative rates were respectively 31.57% ,81.58% ,94.74% and 97.37% at weeks 4,12,24 and 48 after treatment,HBVDNA in PBMCs negative rates were 10. 52% 、42.12% 、57.89% 、76.32% in treatment group,respectively.The difference between HBVDNA negative rate in serum and PBMCs in treatment group and control group was significant( P < 0.005) .Conclusion HBVDNA in serum and PBMCs was significantly inhibited in chronic hepatitis B patients treated with Entecavir,but HB-VDNA in PBMCs negative rate was lower than Serum HBVDNA negative rate.